... for patients with bleeding disorders, we established new clinical teams for our hemophilia treatment center (HTC). Aims: We undertook a quality improvement project to improve the coordination and communication with our patients by establishing primary assignments of clinical staff to individual patients...

...Elena Santagostino; Guy Young; Carmen Escuriola Ettingshausen; Victor Jimenez-Yuste; Manuel Carcao The development of inhibitors against factor VIII (FVIII) concentrates represents a significant treatment complication for hemophilia. Immune tolerance induction (ITI) therapy eradicates inhibitors...

...Christina Schnohr; Theis Bacher; Terkel Andersen; Lars Lehrmann; Eva Funding; Lone Hvitfeldt Poulsen; Karen Binger Holm; Jakob B. Bjorner Background: The positive effects of factor treatment of hemophilia are well established, but the long-term outcomes are not well documented. This panel study...

...S. van Creveld† A description of the continued experience acquired by transfusion of cryoprecipitates respectively 2 and 3 times a week in the prophylactic treatment of 2 young patients with hemophilia A now extending over periods of almost 3 years and more than 2½ years. The conclusion that with 3...

...A. Girolami; G. Cella The occurrence of an acute superficial phle bitis in a patient with hemophilia A is reported. The patient is a 29-year-old hemophiliac who was hospitalized because of a severe posttraumatic left knee hemarthrosis.The phlebitic changes involved the left basilic vein...

...K. Lechner The inhibitor-neutralizing capacity of the plasmas of 101 patients with hemophilia A and 16 with was deter- Factor mined, using a natural antibody against factor VIII. In 48 patients with severe hemophilia A, no inhibitor- neutralizing material was detectable. The plasmas of Von...

... as having IBS. All patients were referred because of moderate-to-severe bleeding diatheses; they included 52 hemophiliacs, 27 patients with von Willebrand’s disease, 4 with hemophilia B (IX-deficit), 2 with afibrinogenemia, 1 with prothrombin deficiency, and 4 were thought to have platelet dysfunction...

..., instructions or products referred to in the content or advertisements. Anti-A antibody Factor VIII concentrate Hemolytic anemia Hemophilia Acta haemat. 58: 294-297 (1977) Hemophiliac with Hemolytic Anemia Resulting from Factor VIII Concentrate Nalin S. Soni, A shok R. P atel, R. M ala V ohra and P...

... Catea , J. W.P. Marsmanh, C. Breedervelda-' Regional Amsterdam Hemophilia Centre, Department of Hematology, Division of Hemostasis and Thrombosis, and hDepartment of Radiology, University Hospital Wilhelmina Gasthuis , Amsterdam, The Netherlands Key Words. Arterial rupture Hemophilia Iliopsoas...

... by Polyarticular Septic Arthritis1 Jonathan C. Goldsmith, Peter T. Silberstein, Robert E. Fromm, Jr., Delores Y. Walker Department of Internal Medicine and the Great Plains Regional Hemophilia Center, University of Iowa, Iowa City, Iowa, USA Key Words. Arthritis Hemophilia Pyarthrosis Abstract. A case...

...Toshio Hattori; Shojiro Ikematsu; Toru Chosa; Seiko Yamamoto; Masao Matsuoka; Katsuhiro Fukutake; Marjorie Robert-Guroff; Kiyoshi Takatsuki Sera from 154 hemophiliacs, including 132 with hemophilia A and 22 with hemophilia B, were examined for antibodies against human T cell lymphotropic virus type...

...Judith A. Wilimas; Gerald Presbury; David Orenstein; Gary V. Dahl; Winfred Wang; Marion Dugdale Three patients with hemophilia presented with hemothoraces which resolved within 1–3 weeks following treatment with factor concentrates. Drainage of blood was not necessary. Eight previously reported...

...A. Berghout; W.M.C. Mallens; J. te Velde; H.L. Haak We describe a patient with hemophilia A and primary malignant teratoma of the lung. Hemothorax and pseudotumor in hemophilia are rare disorders and can raise many differential diagnostic problems 18 11 1982 5 05 1983 25 2 2009...

... or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Anti-idiotypic antibodies Factor VIII inhibitors Hemophilia...

... virus (HIV)– and HIV+ patients with congenital bleeding disorders. Between 2000 and 2004, 50 (18–68 years old) patients with CHC (19 HIV+) from two hemophilia centers were included in the study. They were treated with weekly subcutaneous administration of Peg-INF-α combined with 800–1,200 mg ribavirin...

... to be due to a chance association between heterozygotes for FVII deficiency and those for FX defects. In a few instances, combined FVII and FX deficiency also showed an association with non-coagulation-related defects. Several cases had FVII deficiency concomitant with hemophilia A, being apparently of two...

...Amy L. Dunn; Thomas C. Abshire Factor VIII or IX replacement in a prophylactic manner is utilized for many patients with moderate to severe hemophilia A or B. Studies have shown it to be effective in reducing or preventing degenerative joint disease in many but not all patients. However, many...

...Guy Young The most serious current complication of factor replacement therapy for hemophilia patients is the development of neutralizing antibodies to the factor termed inhibitors. Patients with high-titer inhibitors frequently develop serious bleeding complications which do not respond to standard...

... and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Cytomegalovirus Gastrointestinal bleeding Hemophilia Polymerase chain reaction Cytomegalovirus (CMV...

... serum levels of fibrotic markers and histological scores. A p value <0.05 was considered statistically significant. Hemophilia Hepatitis C virus Hyaluronan Hyaluronic acid Interferon Liver fibrosis Almost all hemophiliacs who received clotting factor concentrates before...